Optimizing the Continuum of Care in Gastric Cancer

References

• Yan S, Gan Y, Song X, et al. Association between refrigerator use and the risk of gastric cancer: a systematic review and meta-analysis of observational studies. PLoS One. 2018;13(8):e0203120. doi:10.1371/journal.pone.0203120
   PubMed Web of Science ®Google Scholar
• Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Coch Datab System Rev. 2020;2020:1. doi:10.1002/14651858.CD005583.pub3
   Google Scholar
• Choi KS, Jun JK, Suh M, et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the national cancer screening programme in Korea. Br J Cancer. 2015;112(3):608–612. doi:10.1038/bjc.2014.608
   PubMed Web of Science ®Google Scholar
• Fan X, Qin X, Zhang Y, et al. Screening for gastric cancer in China: advances, challenges and visions. Chin J Can Res. 2021;33(2):168–180. doi:10.21147/j.issn.1000-9604.2021.02.05
   PubMed Web of Science ®Google Scholar
• Acuna N, Park SY, Le Marchand L, et al. Diet quality and risk of gastric adenocarcinoma: the multiethnic cohort. Am J Clin Nutr. 2023;117(1):46–54. doi:10.1016/j.ajcnut.2022.11.009
   PubMed Web of Science ®Google Scholar
• Tayyem R, AL-Awwad N, Allehdan S, et al. Mediterranean dietary pattern is associated with lower odds of gastric cancer: a case–control study. CMAR. 2022;14:2017–2029. doi:10.2147/CMAR.S360468
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA a Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789. doi:10.1002/ijc.33588
   Web of Science ®Google Scholar
• Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. eClin Med. 2022:47. doi:10.1016/j.eclinm.2022.101404
   Google Scholar
• Arnold M, Morgan E, Bardot A, et al. International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study). Gut. 2022;71(8):1532. doi:10.1136/gutjnl-2021-325266
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, Rocha PRS, Rodrigues MAG, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72(1):37–41. doi:10.1002/1097-0142(19930701)72:1
   PubMed Web of Science ®Google Scholar
• Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Coch Datab System Rev. 2017;2017(8). doi:10.1002/14651858.CD004064.pub4
   Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi:10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. doi:10.1016/S0140-6736(21)00797-2
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Kang YK, Saeed A, et al. FIGHT: a randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). JCO. 2021;39(15_suppl):4010. doi:10.1200/JCO.2021.39.15_suppl.4010
   Web of Science ®Google Scholar
• Al-Batran SE, Schuler MH, Zvirbule Z, et al. FAST: an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. JCO. 2016;34(18_suppl):LBA4001–LBA4001. doi:10.1200/JCO.2016.34.18_suppl.LBA4001
   Web of Science ®Google Scholar
• Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–2430. doi:10.1056/NEJMoa2004413
   PubMed Web of Science ®Google Scholar
• Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Anna Oncol. 2022;33(10):1005–1020. doi:10.1016/j.annonc.2022.07.004
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. doi:10.1056/NEJMoa073149
   PubMed Web of Science ®Google Scholar
• Hall PS, Swinson D, Cairns DA, et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 Phase 3 randomized clinical trial. JAMA Oncol. 2021;7(6):869–877. doi:10.1001/jamaoncol.2021.0848
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. JCO. 2011;29(30):3968–3976. doi:10.1200/JCO.2011.36.2236
   PubMed Web of Science ®Google Scholar
• Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–499. doi:10.1016/S1470-2045(13)70102-5
   PubMed Web of Science ®Google Scholar
• Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481–489. doi:10.1016/S1470-2045(13)70096-2
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(11):1467–1482. doi:10.1016/S1470-2045(17)30566-1
   PubMed Web of Science ®Google Scholar
• Shah MA, Bang YJ, Lordick F, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-Negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 2017;3(5):620–627. doi:10.1001/jamaoncol.2016.5580
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):420–435. doi:10.1016/S1470-2045(18)30791-5
   PubMed Web of Science ®Google Scholar
• Shah MA, hua XR, Bang YJ, et al. HELOISE: phase iiib randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2–positive metastatic gastric or gastroesophageal junction adenocarcinoma. JCO. 2017;35(22):2558–2567. doi:10.1200/JCO.2016.71.6852
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—A randomized phase III trial. JCO. 2016;34(5):443–451. doi:10.1200/JCO.2015.62.6598
   PubMed Web of Science ®Google Scholar
• Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–1384. doi:10.1016/S1470-2045(18)30481-9
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571. doi:10.1001/jamaoncol.2020.3370
   PubMed Web of Science ®Google Scholar
• Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942–948. doi:10.1038/s41586-022-04508-4
   PubMed Web of Science ®Google Scholar
• Xu J, Jiang H, Pan Y, et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study. Anna Oncol. 2021;32:S1331. doi:10.1016/j.annonc.2021.08.2133
   Web of Science ®Google Scholar
• Moehler M, Dvorkin M, Boku N, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100. JCO. 2021;39(9):966–977. doi:10.1200/JCO.20.00892
   PubMed Web of Science ®Google Scholar
• Stein A, Paschold L, Tintelnot J, et al. Efficacy of Ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial. JAMA Oncol. 2022;8(8):1150–1158. doi:10.1001/jamaoncol.2022.2228
   PubMed Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482–491. doi:10.1038/onc.2009.356
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–443. doi:10.1158/2326-6066.CIR-15-0064
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. doi:10.1016/S0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234–247. doi:10.1016/S1470-2045(21)00692-6
   PubMed Web of Science ®Google Scholar
• Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–337. doi:10.5858/arpa.2018-0043-OA
   PubMed Web of Science ®Google Scholar
• Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability–high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895. doi:10.1001/jamaoncol.2021.0275
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–831. doi:10.1016/S1470-2045(20)30169-8
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–730. doi:10.1038/s41586-021-04161-3
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–39. doi:10.1016/S0140-6736(13)61719-5
   PubMed Web of Science ®Google Scholar
• Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. JCO. 2012;30(13):1513–1518. doi:10.1200/JCO.2011.39.4585
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306–2314. doi:10.1016/j.ejca.2011.06.002
   PubMed Web of Science ®Google Scholar
• Ford HER, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78–86. doi:10.1016/S1470-2045(13)70549-7
   PubMed Web of Science ®Google Scholar
• Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Coch Datab System Rev. 2020;2020:11. doi:10.1002/14651858.CD012078.pub2
   Google Scholar
• Kanagavel D. Second-line treatment of metastatic gastric cancer: current options and future directions. WJG. 2015;21(41):11621. doi:10.3748/wjg.v21.i41.11621
   PubMed Web of Science ®Google Scholar
• Digklia A. Advanced gastric cancer: current treatment landscape and future perspectives. WJG. 2016;22(8):2403. doi:10.3748/wjg.v22.i8.2403
   PubMed Web of Science ®Google Scholar
• Cotes Sanchís A, Gallego J, Hernandez R, et al. Second-line treatment in advanced gastric cancer: data from the Spanish AGAMENON registry. PLoS One. 2020;15(7):e0235848. doi:10.1371/journal.pone.0235848
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–1235. doi:10.1016/S1470-2045(14)70420-6
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. JCO. 2020;38(1):1–10. doi:10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Anna Oncol. 2022;33(9):929–938. doi:10.1016/j.annonc.2022.05.519
   PubMed Web of Science ®Google Scholar
• Tabernero J, Shitara K, Zaanan A, et al. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO Open. 2021;6(4):100200. doi:10.1016/j.esmoop.2021.100200
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. JCO. 2016;34(13):1448–1454. doi:10.1200/JCO.2015.63.5995
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Tada M, Horikoshi N, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer. 2002;5(2):90–95. doi:10.1007/s101200200015
   PubMedGoogle Scholar
• Yamada Y, Shirao K, Ohtsu A, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Anna Oncol. 2001;12(8):1133–1137. doi:10.1023/A:1011680507956
   PubMed Web of Science ®Google Scholar
• Koizumi W, Akiya T, Sato A, et al. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 trial. Jpn J Clin Oncol. 2009;39(11):713–719. doi:10.1093/jjco/hyp099
   PubMed Web of Science ®Google Scholar
• Kodera Y, Ito S, Mochizuki Y, et al. A Phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 Study). Anticancer Res. 2007;2007:1.
   Google Scholar
• Shimoyama R, Yasui H, Boku N, et al. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer. 2009;12(4):206–211. doi:10.1007/s10120-009-0524-9
   PubMed Web of Science ®Google Scholar
• Im CK, Rha SY, Jeung HC, et al. A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status. Oncology. 2009;77(6):349–357. doi:10.1159/000265941
   PubMed Web of Science ®Google Scholar
• Matsuda G, Kunisaki C, Makino H, et al. Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer. Anticancer Res. 2009;29:2863–2867.
   PubMed Web of Science ®Google Scholar
• Shitara K, Takashima A, Fujitani K, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(4):277–287. doi:10.1016/s2468-1253(16)30219-9
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo M, Niger M, Tirino G, et al. Ramucirumab as second-line therapy in metastatic gastric cancer: real-world data from the RAMoss study. Target Oncol. 2018;13(2):227–234. doi:10.1007/s11523-018-0562-5
   PubMed Web of Science ®Google Scholar
• Han HS, Kim BJ, Jee HJ, et al. Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). Ther Adv Med Oncol. 2021;13:17588359211042812. doi:10.1177/17588359211042812
   Web of Science ®Google Scholar
• Longo F, Jorge M, Yaya R, et al. Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study. Fut Oncol. 2021;17(14):1777–1791. doi:10.2217/fon-2020-1216
   PubMed Web of Science ®Google Scholar
• Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437–1448. doi:10.1016/S1470-2045(18)30739-3
   PubMed Web of Science ®Google Scholar
• Ilson DH, Tabernero J, Prokharau A, et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial. JAMA Oncol. 2020;6(1):e193531. doi:10.1001/jamaoncol.2019.3531
   PubMed Web of Science ®Google Scholar
• Tabernero J, Alsina M, Shitara K, et al. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. Gastric Cancer. 2020;23(4):689–698. doi:10.1007/s10120-020-01053-9
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Shitara K, Sjoquist KM, et al. INTEGRATE IIa: a randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG). JCO. 2023;41(4_suppl):LBA294–LBA294. doi:10.1200/JCO.2023.41.4_suppl.LBA294
   Google Scholar
• Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957. doi:10.1016/s0140-6736(18)32557-1
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Thuss-Patience P, Pauligk C, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS study of the German gastric cancer study group at AIO. Eur J Cancer. 2022;165:48–57. doi:10.1016/j.ejca.2022.01.015
   PubMed Web of Science ®Google Scholar
• Tey J, Back MF, Shakespeare TP, et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys. 2007;67(2):385–388. doi:10.1016/j.ijrobp.2006.08.070
   PubMed Web of Science ®Google Scholar
• Tey J, Soon YY, Koh WY, et al. Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(15):25797–25805. doi:10.18632/oncotarget.15554
   PubMedGoogle Scholar
• Kim MM, Kim MM, Rana V, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47(3):421–427. doi:10.1080/02841860701621233
   PubMed Web of Science ®Google Scholar
• Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. 2011;14(2):97–100. doi:10.1007/s10120-011-0040-6
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Gastric Cancer. Version 2; 2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed November 16, 2023.
   Google Scholar
• Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–318. doi:10.1016/S1470-2045(15)00553-7
   PubMed Web of Science ®Google Scholar
• Zhang JF, Lv L, Zhao S, Zhou Q, Jiang CG. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: a 12-year meta-analysis of this promising treatment strategy for advanced gastric cancer at different stages. Ann Surg Oncol. 2022;29(5):3170–3186. doi:10.1245/s10434-021-11316-z
   PubMed Web of Science ®Google Scholar
• Granieri S, Bonomi A, Frassini S, et al. Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: a meta-analysis of randomized controlled trials. Eur J Surg Oncol. 2021;47(11):2757–2767. doi:10.1016/j.ejso.2021.05.016
   PubMed Web of Science ®Google Scholar
• Rau B, Feldbrügge L, Gronau F, et al. Indication of hyperthermic intraperitoneal chemotherapy in gastric cancer (Gastripec, Gastrichip). Visc Med. 2022;38(2):81–89. doi:10.1159/000522604
   PubMed Web of Science ®Google Scholar
• Lu Z, Fang Y, Liu C, et al. Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: a phase iii randomized controlled trial. JCO. 2021;39(7):748–756. doi:10.1200/JCO.20.01254
   PubMed Web of Science ®Google Scholar
• Rimini M, Pecchi A, Prampolini F, et al. The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: a Pilot Experience from Modena Cancer Center. J Clin Med. 2021;10(8):1705. doi:10.3390/jcm10081705
   PubMed Web of Science ®Google Scholar
• Kamarajah SK, Bundred J, Tan BHL. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(1):10–22. doi:10.1007/s10120-018-0882-2
   PubMed Web of Science ®Google Scholar
• Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Anna Oncol. 2016;27:v119–v133. doi:10.1093/annonc/mdw270
   PubMed Web of Science ®Google Scholar
• Mendelsohn RB, Gerdes H, Markowitz AJ, DiMaio CJ, Schattner MA. Carcinomatosis is not a contraindication to enteral stenting in selected patients with malignant gastric outlet obstruction. Gastrointest Endosc. 2011;73(6):1135–1140. doi:10.1016/j.gie.2011.01.042
   PubMed Web of Science ®Google Scholar
• Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esoph. 2005;18(3):131–139. doi:10.1111/j.1442-2050.2005.00467.x
   PubMed Web of Science ®Google Scholar
• Min SH, Son SY, Jung DH, et al. Laparoscopic gastrojejunostomy versus duodenal stenting in unresectable gastric cancer with gastric outlet obstruction. Ann Surg Treat Res. 2017;93(3):130–136. doi:10.4174/astr.2017.93.3.130
   PubMed Web of Science ®Google Scholar
• Sandhya L, Devi Sreenivasan N, Goenka L, et al. Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. JCO. 2023;41(14):2617–2627. doi:10.1200/JCO.22.01997
   PubMed Web of Science ®Google Scholar
• Sepúlveda C, Marlin A, Yoshida T, Ullrich A. Palliative care: the world health organization’s global perspective. J Pain Symptom Manage. 2002;24(2):91–96. doi:10.1016/S0885-3924(02)00440-2
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013
   PubMed Web of Science ®Google Scholar
• Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–133. doi:10.1016/S0140-6736(18)31257-1
   PubMed Web of Science ®Google Scholar
• Tabernero J, Bang YJ, Van Cutsem E, et al. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. Fut Oncol. 2021;17(22):2847–2855. doi:10.2217/fon-2021-0176
   PubMed Web of Science ®Google Scholar
• hua XR, Arkenau HT, Bang YJ, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. JCO. 2020;38(4_suppl):TPS458–TPS458. doi:10.1200/JCO.2020.38.4_suppl.TPS458
   Web of Science ®Google Scholar
• Herbst RS, Arkenau HT, Santana-Davila R, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019;20(8):1109–1123. doi:10.1016/S1470-2045(19)30458-9
   PubMed Web of Science ®Google Scholar
• Högner A, Breithaupt K, Stein A, et al. RAP: a phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO). JCO. 2019;37(15_suppl):TPS4148–TPS4148. doi:10.1200/JCO.2019.37.15_suppl.TPS4148
   Web of Science ®Google Scholar
• Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(8):1057–1065. doi:10.1016/S1470-2045(20)30271-0
   PubMed Web of Science ®Google Scholar
• Tabernero J, Cohen D, Van Cutsem E, et al. P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015. Anna Oncol. 2021:32:S151–S152. doi:10.1016/j.annonc.2021.05.209
   Google Scholar
• Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603). JCO. 2020;38(18):2053–2061. doi:10.1200/JCO.19.03296
   PubMed Web of Science ®Google Scholar
• Athauda A, Chau I. Claudin 18.2-a FAST-moving target in gastric cancer? Anna Oncol. 2021;32(5):3. doi:10.1016/j.annonc.2021.02.021
   Web of Science ®Google Scholar
• Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133–2141. doi:10.1038/s41591-023-02465-7
   PubMed Web of Science ®Google Scholar
• Kubota Y, Kawazoe A, Mishima S, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8(1):100762. doi:10.1016/j.esmoop.2022.100762
   PubMed Web of Science ®Google Scholar
• Türeci O, Sahin U, Schulze-Bergkamen H, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Anna Oncol. 2019;30(9):1487–1495. doi:10.1093/annonc/mdz199
   PubMed Web of Science ®Google Scholar
• Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: primary results from phase 3 SPOTLIGHT study. JCO. 2023;41(4_suppl):LBA292–LBA292. doi:10.1200/JCO.2023.41.4_suppl.LBA292
   Web of Science ®Google Scholar
• Rha SY, Lee Kun C, Kim HS, et al. The first report of K-umbrella gastric cancer study: an open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC). JCO. 2022;40(16_suppl):4001. doi:10.1200/JCO.2022.40.16_suppl.4001
   Web of Science ®Google Scholar
• Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Anna Oncol. 2021;32(6):746–756. doi:10.1016/j.annonc.2021.03.005
   PubMed Web of Science ®Google Scholar
• Gall VA, Philips AV, Qiao N, et al. Trastuzumab Increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res. 2017;77(19):5374–5383. doi:10.1158/0008-5472.CAN-16-2774
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qiu M, Wang J, et al. A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01). JCO. 2021;39(15_suppl):e16059–e16059. doi:10.1200/JCO.2021.39.15_suppl.e16059
   Web of Science ®Google Scholar
• Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study. Cancer Commun. 2021;41(11):1173–1182. doi:10.1002/cac2.12214
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. Lancet Oncol. 2020;21(8):1066–1076. doi:10.1016/S1470-2045(20)30326-0
   PubMed Web of Science ®Google Scholar
• Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Fut Oncol. 2021;17(10):1155–1164. doi:10.2217/fon-2020-1007
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Beeram M, Mayordomo JI, et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. JCO. 2018;36(15_suppl):2500. doi:10.1200/JCO.2018.36.15_suppl.2500
   Web of Science ®Google Scholar
• Gong J, Shen L, Luo S, et al. 1377P Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors. Anna Oncol. 2021;32:S1042. doi:10.1016/j.annonc.2021.08.1486
   Web of Science ®Google Scholar
• Catenacci DVT, Strickler JH, Nakamura Y, et al. MOUNTAINEER-02: phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in progress. JCO. 2022;40(4_suppl):TPS371–TPS371. doi:10.1200/JCO.2022.40.4_suppl.TPS371
   Web of Science ®Google Scholar
• Laeufle R, Maglakelidze M, Bulat I, et al. HERIZON: a phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. JCO. 2021;39(15_suppl):e16065–e16065. doi:10.1200/JCO.2021.39.15_suppl.e16065
   Web of Science ®Google Scholar
• Reiss K, Yuan Y, Barton D, et al. 951 A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data. J Immunother Cancer. 2021;9(Suppl 2):A1000–A1000. doi:10.1136/jitc-2021-SITC2021.951
   Google Scholar
• Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for research and treatment of cancer gastrointestinal tract cancer cooperative group. JCO. 2000;18(14):2648–2657. doi:10.1200/JCO.2000.18.14.2648
   PubMed Web of Science ®Google Scholar
• Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. JCO. 2014;32(31):3520–3526. doi:10.1200/JCO.2013.54.1011
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. JCO. 2008;26(9):1435–1442. doi:10.1200/JCO.2007.13.9378
   PubMed Web of Science ®Google Scholar